Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02779777
Title Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kura Oncology, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Columbia University Medical Center New York New York 10032 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field